Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why BHVN stock is a hold.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

TANZANIA is among countries expected to benefit from the upcoming rollout of injectable lenacapavir for HIV prevention, following a landmark recommendation by the World Health Organization (WHO).